03593nas a2200313 4500000000100000008004100001260001200042653002600054653002600080653002300106653003900129100001700168700001400185700001400199700001300213700001600226700002000242700001300262700001900275700001300294700001100307700001200318245022300330856016700553300001000720490000800730520252700738022001403265 2020 d c09/202010aCommunicable diseases10aGuideline development10aResearch questions10aNeglected tropical diseases (NTDs)1 aHargreaves S1 aHimmels J1 aNellums L1 aBiswas G1 aGabrielli A1 aGebreselassie N1 aZignol M1 aSchellenberg D1 aNorris S1 aFord N1 aMaher D00aIdentifying research questions for HIV, tuberculosis, tuberculosis-HIV, malaria, and neglected tropical diseases through the World Health Organization guideline development process: a retrospective analysis, 2008-2018. uhttps://reader.elsevier.com/reader/sd/pii/S0033350620300925?token=ED84BAAED4100089C817B743D92C4DCA493D802E424196799CD8AFB804977AFD654BCDE4085A39192736622B23A84562 a19-230 v1873 a
OBJECTIVES: World Health Organization (WHO) guidelines for health programmes and healthcare delivery are the foundation of its technical leadership in public health and essential to decision-making globally. A key function of guideline development is to identify areas in which further evidence is needed because filling these gaps will lead to future improvements in population health. The objective of this study was to examine the knowledge gaps and research questions for addressing those gaps generated through the WHO guideline development process, with the goal of informing future strategies for improving and strengthening the guideline development process.
STUDY DESIGN: We did a systematic, retrospective analysis of research questions identified in the published guidelines.
METHODS: We analyzed guidelines published between January 1, 2008, and December 31, 2018, by the Communicable Diseases Cluster in five disease areas: tuberculosis (TB), HIV, malaria, TB-HIV, and neglected tropical diseases (NTDs). Research questions were extracted independently by two researchers. We analyzed the distribution of research questions by disease and by topic category and did a qualitative assessment of optimum practice for research question generation during the guideline development process.
RESULTS: A total of 48 guidelines were included: 26 on HIV, 1 on malaria, 11 on TB, 5 on TB/HIV, and 5 on NTDs. Overall, 36 (75%) guidelines encompassed a total of 360 explicit research questions; the remainder did not contain specific research questions. The number of research questions that focused on TB was 49, TB/HIV was 38, HIV was 250, and NTDs was 23. The number of research questions that focused on diagnosis was 43 (11.9%) of 360, prevention was 62 (17.2%), treatment was 103 (28.6%), good practice was 12 (3.3%), service delivery was 86 (23.8%), and other areas was 54 (15%). Research questions were often not formulated in a specific or actionable way and were hard to identify in the guideline. Examples of good practice identified by the review team involved the generation of specific and narrowly defined research questions, with accompanying recommendations for appropriate study design.
CONCLUSIONS: The WHO must strengthen its approach to identifying and presenting research questions during the guideline development process. Ensuring access to research questions is a key next step in adding value to the guideline development process.
a1476-5616